BR0016635A - Moduladores de neurotransmissão de dopamina - Google Patents

Moduladores de neurotransmissão de dopamina

Info

Publication number
BR0016635A
BR0016635A BR0016635-9A BR0016635A BR0016635A BR 0016635 A BR0016635 A BR 0016635A BR 0016635 A BR0016635 A BR 0016635A BR 0016635 A BR0016635 A BR 0016635A
Authority
BR
Brazil
Prior art keywords
alkyl
oso
furan
thiophene
och
Prior art date
Application number
BR0016635-9A
Other languages
English (en)
Inventor
Andersson Bengt
Clas Sonesson
Susanna Waters
Nicholas Waters
Joakim Tedroff
Original Assignee
Carlsson A Research Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlsson A Research Ab filed Critical Carlsson A Research Ab
Publication of BR0016635A publication Critical patent/BR0016635A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Liquid Crystal Substances (AREA)
  • Control Of El Displays (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Error Detection And Correction (AREA)

Abstract

"MODULADORES DE NEUROTRANSMISSãO DE DOPAMINA". Novos compostos de 4-(fenil-N-alquil)piperazina substituída ou e 4-(fenil-N-alquil)pipeúdina substituída da Fórmula (1) em que X é N, CH e C, contudo, X só pode ser C quando o composto compreende uma ligação dupla na linha pontilhada; R~ 1~ é CF~ 3~, OSO~ 2~CF~ 3~, OSO~ 2~CH~ 3~, SOR~ 7~, SO~ 2~R~ 7~, COR~ 7~, CN, OR~ 3~, NO~ 2~, CONHR~ 3~, 3-tiofeno, 2-tiofeno, 3-furano, 2-furano, F, Cl, Br ou I; R~ 2~ é F, CI, Br, I, CN, CF~ 3~,CH~ 3~, OCH~ 3~,OH e NH~ 2~; R~ 3~ e R~ 4~ são independentemente H e C~ 1~-C~ 4~ alquila; R~ 5~ é C~ 1~-C~ 4~ alquila, alila, CH~ 2~SCH~ 3~, CH~ 2~CH~ 2~OCH~ 3~, CH~ 2~CH~ 2~CH~ 2~F, CH~ 2~CF~ 3~, 3,3,3-trifluoropropila, 4,4,4-trifluorobutila ou -(CH~ 2~)-R~ 6~; R~ 6~ é C~ 3~-C~ 6~ cicloalquilas, 2-tetraidrofurano e 3-tetraidrofurano; R~ 7~ e C-C~ 3~ alquila, CF~ 3~ e N(R~ 4~)~ 2~; e sais farmaceuticamente aceitáveis dos mesmos são descritos. Também, composições farmacêuticas compreendendo os compostos acima e métodos em que os compostos acima são usados para o tratamento de distúrbios no sistema nervoso central são descritos.
BR0016635-9A 1999-12-22 2000-12-22 Moduladores de neurotransmissão de dopamina BR0016635A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904723A SE9904723D0 (sv) 1999-12-22 1999-12-22 New modulators of dopamine neurotransmission II
PCT/SE2000/002675 WO2001046146A1 (en) 1999-12-22 2000-12-22 New modulators of dopamine neurotransmission

Publications (1)

Publication Number Publication Date
BR0016635A true BR0016635A (pt) 2002-10-15

Family

ID=20418252

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016635-9A BR0016635A (pt) 1999-12-22 2000-12-22 Moduladores de neurotransmissão de dopamina

Country Status (30)

Country Link
US (2) USRE41315E1 (pt)
EP (2) EP1419773B1 (pt)
JP (1) JP5096654B2 (pt)
KR (1) KR100771287B1 (pt)
CN (1) CN1196680C (pt)
AT (1) ATE397446T1 (pt)
AU (1) AU778183B2 (pt)
BG (1) BG65698B1 (pt)
BR (1) BR0016635A (pt)
CA (1) CA2394606C (pt)
CZ (1) CZ302907B6 (pt)
DE (1) DE60039131D1 (pt)
DK (1) DK1419773T3 (pt)
EE (1) EE05083B1 (pt)
ES (1) ES2307861T3 (pt)
HK (1) HK1054228B (pt)
HR (1) HRP20020539B1 (pt)
HU (1) HUP0203874A3 (pt)
IL (2) IL150350A0 (pt)
MX (1) MXPA02006317A (pt)
NO (1) NO323329B1 (pt)
NZ (2) NZ519566A (pt)
PL (1) PL205092B1 (pt)
PT (1) PT1419773E (pt)
RU (1) RU2262504C2 (pt)
SE (1) SE9904723D0 (pt)
SK (1) SK287366B6 (pt)
UA (1) UA73337C2 (pt)
WO (1) WO2001046146A1 (pt)
ZA (1) ZA200204813B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
WO2004113297A2 (en) * 2003-06-24 2004-12-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
ATE449071T1 (de) * 2004-06-08 2009-12-15 Nsab Af Neurosearch Sweden Ab Neue substituierte piperidine als modulatoren der dopamin neurotransmission
SE0401464D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
ES2346452T3 (es) 2004-06-08 2010-10-15 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Nuevas fenilpiperidinas/piperazinas disustituidas utilizadas como moduladores de la neurotransmision de la dopamina.
MXPA06013941A (es) * 2004-06-08 2007-12-10 Neurosearch Sweden Ab Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
JP2008502652A (ja) * 2004-06-18 2008-01-31 ノイロサーチ アクティーゼルスカブ モノアミン神経伝達物質再取込み阻害剤としての、新規アルキル置換ピペラジン誘導体及びその使用
EP1807394A1 (en) * 2004-10-13 2007-07-18 Neurosearch Sweden AB Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
ITMI20051193A1 (it) * 2005-06-24 2006-12-25 Acraf Uso farmaceutico di una 1-3-clorofenil-3-alchilpiperazina
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US20080269286A1 (en) 2005-12-07 2008-10-30 Clas Sonesson Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission
CN101711236B (zh) * 2007-04-12 2012-10-31 Nsab神经研究瑞典公司分公司 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物
AU2008258597A1 (en) 2007-06-05 2008-12-11 Nsab, Filial Af Neurosearch Sweden Ab, Sverige New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
AU2008258599B2 (en) 2007-06-05 2013-06-13 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
MX2010011724A (es) * 2008-04-29 2010-11-30 Nsab Af Neurosearch Sweden Ab Moduladores de neurotransmision de dopamina.
EP2271638B1 (en) * 2008-04-29 2011-08-31 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
JP2011519839A (ja) * 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
BR112014005389A8 (pt) 2011-09-07 2018-04-03 Ivax Int Gmbh Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
BR112021023563A2 (pt) * 2019-05-24 2022-01-04 Integrative Res Laboratories Sweden Ab Sais farmaceuticamente aceitáveis de [2-(3-fluoro-5-metano-sulfonilfenóxi)etil](propil) amina e usos dos mesmos
CN116554127B (zh) * 2022-01-28 2025-03-21 成都麻沸散医药科技有限公司 哌嗪取代苯酚类衍生物及其用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2027703A (en) * 1934-06-21 1936-01-14 Ribar Peter Shoe jack
DE1019308B (de) * 1954-07-19 1957-11-14 Hoechst Ag Verfahren zur Herstellung gegen Bilharzia-Infektionen wirksamer 4-Phenyl-piperazine
GB850662A (en) 1956-10-22 1960-10-05 Parke Davis & Co Substituted piperazines and processes for their production
BE662455A (pt) 1964-04-14
GB1060160A (en) 1964-08-05 1967-03-01 Allen & Hanburys Ltd 4-phenylpiperidine derivatives
NL6607959A (pt) * 1965-06-10 1966-12-12
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
CA1061356A (en) * 1975-10-03 1979-08-28 Dieter H. Klaubert 2-cyano-3- or 4-(substituted amino) oxanilic acid derivatives
GB1560271A (en) 1977-01-14 1980-02-06 Joullie International Sa Therapeutically useful m-trifluoromethylphenylpiperazine derivatives
US4202898A (en) * 1978-06-05 1980-05-13 Synthelabo Method of treating anxiety and depression
FR2459797A2 (fr) * 1978-08-01 1981-01-16 Synthelabo Derives de phenyl-1 piperazine et leur application en therapeutique
US4267328A (en) 1978-08-01 1981-05-12 Synthelabo 1-Phenylpiperazines
US4333942A (en) 1979-08-03 1982-06-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Anti-depressant and analgesic 4-phenoxypiperidines
JPS5714585A (en) * 1980-06-30 1982-01-25 Taiho Yakuhin Kogyo Kk 1-cycloalkylmethylpiperazine derivative
US4518712A (en) * 1980-06-30 1985-05-21 Taiho Pharmaceutical Company Limited Piperazine derivative and analgesic composition containing the same
GB2083476B (en) * 1980-09-12 1984-02-08 Wyeth John & Brother Ltd Heterocyclic compounds
FR2501506A1 (fr) 1981-03-11 1982-09-17 Sanofi Sa Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
JPS5815979A (ja) * 1981-07-11 1983-01-29 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体およびその製造法
US4415736A (en) 1981-12-28 1983-11-15 E. I. Du Pont De Nemours & Co. Certain tetrahydropyridine intermediates
ATE50987T1 (de) 1982-05-10 1990-03-15 Takeda Chemical Industries Ltd Dihydropyridinderivate, deren herstellung und verwendung.
US4504660A (en) 1982-07-06 1985-03-12 American Home Products Corporation Process for the production of 2,6-diaminobenzonitrile derivatives
ES540226A0 (es) * 1985-02-07 1985-12-01 Inst Investigacion Desarrollo Un nuevo procedimiento de obtencion de derivados del acido quinolincarboxilico
US4892975A (en) 1987-09-28 1990-01-09 President And Fellows Of Harvard College Diethynyl monomers and polymers thereof
HU198454B (en) 1987-12-14 1989-10-30 Richter Gedeon Vegyeszet Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
CA2071897A1 (en) * 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
WO1992018475A2 (en) 1991-04-17 1992-10-29 The Upjohn Company Substituted phenylazacycloalkanes as cns agents
AU676993B2 (en) * 1991-06-27 1997-04-10 Virginia Commonwealth University Sigma receptor ligands and the use thereof
IE914218A1 (en) 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
PT533268E (pt) 1991-09-18 2002-02-28 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
TW240217B (pt) * 1992-12-30 1995-02-11 Glaxo Group Ltd
GB2276160A (en) * 1993-03-17 1994-09-21 Glaxo Group Ltd Ethanone compounds.
US5502050A (en) * 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
EP0659743A1 (en) 1993-12-27 1995-06-28 Hoechst Aktiengesellschaft Piperidine derivatives as inhibitors of platelet aggregation and their preparation
CA2144669A1 (en) * 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
US5571822A (en) * 1994-09-30 1996-11-05 The University Of North Carolina At Chapel Hill Antitumor compounds
AU6470096A (en) 1995-07-19 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. Fused triazole compounds
FR2740134B1 (fr) * 1995-10-18 1998-01-09 Pf Medicament Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
US5892041A (en) 1996-08-12 1999-04-06 Neurogen Corporation Fused indolecarboxamides: dopamine receptor subtype specific ligands
DE19637237A1 (de) 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
US6232326B1 (en) * 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
JP2000086603A (ja) 1998-07-15 2000-03-28 Yoshitomi Pharmaceut Ind Ltd 桂皮酸アミド誘導体および３―フェニルプロピオン酸アミド誘導体
IL146403A0 (en) 1999-06-22 2002-07-25 Neurosearch As Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
US6906120B1 (en) 2000-06-20 2005-06-14 General Electric Poly(arylene ether) adhesive compositions
AU2001280599A1 (en) * 2000-07-15 2002-01-30 Smith Kline Beecham Corporation Compounds and methods
ES2247298T3 (es) 2001-01-23 2006-03-01 Eli Lilly And Company Derivados de piperazina y piperidina como agonistas del receptor de melanocortina.
US6663587B2 (en) * 2001-06-22 2003-12-16 Medela Holding Ag Breastshield with multi-pressure and expansible chamber construction, related breastpump and method
US20050004164A1 (en) 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MXPA06013941A (es) 2004-06-08 2007-12-10 Neurosearch Sweden Ab Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
ES2346452T3 (es) 2004-06-08 2010-10-15 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Nuevas fenilpiperidinas/piperazinas disustituidas utilizadas como moduladores de la neurotransmision de la dopamina.
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US20080269286A1 (en) 2005-12-07 2008-10-30 Clas Sonesson Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission

Also Published As

Publication number Publication date
ZA200204813B (en) 2003-08-27
NZ519566A (en) 2004-05-28
DE60039131D1 (de) 2008-07-17
CA2394606A1 (en) 2001-06-28
JP5096654B2 (ja) 2012-12-12
SK287366B6 (sk) 2010-08-09
PT1419773E (pt) 2008-07-01
KR100771287B1 (ko) 2007-10-29
CN1420870A (zh) 2003-05-28
NO323329B1 (no) 2007-03-26
AU778183B2 (en) 2004-11-18
HRP20020539A2 (en) 2004-08-31
HK1054228A1 (en) 2003-11-21
JP2003518096A (ja) 2003-06-03
WO2001046146A1 (en) 2001-06-28
HUP0203874A2 (hu) 2003-03-28
PL362251A1 (en) 2004-10-18
HK1054228B (zh) 2005-09-16
BG65698B1 (bg) 2009-07-31
CA2394606C (en) 2009-06-02
KR20020067565A (ko) 2002-08-22
EE05083B1 (et) 2008-10-15
US6924374B2 (en) 2005-08-02
BG106845A (en) 2003-04-30
EP1419773A2 (en) 2004-05-19
ATE397446T1 (de) 2008-06-15
IL150350A (en) 2010-05-31
USRE41315E1 (en) 2010-05-04
CN1196680C (zh) 2005-04-13
ES2307861T3 (es) 2008-12-01
SK8662002A3 (en) 2003-02-04
SE9904723D0 (sv) 1999-12-22
NO20022879D0 (no) 2002-06-17
IL150350A0 (en) 2002-12-01
NO20022879L (no) 2002-08-21
AU2570601A (en) 2001-07-03
MXPA02006317A (es) 2004-05-14
CZ20022074A3 (cs) 2002-10-16
HUP0203874A3 (en) 2005-03-29
NZ531643A (en) 2005-03-24
EE200200345A (et) 2003-06-16
EP1240143A1 (en) 2002-09-18
UA73337C2 (en) 2005-07-15
PL205092B1 (pl) 2010-03-31
RU2262504C2 (ru) 2005-10-20
US20030004169A1 (en) 2003-01-02
CZ302907B6 (cs) 2012-01-18
RU2002119417A (ru) 2004-01-10
EP1419773A3 (en) 2004-05-26
HRP20020539B1 (hr) 2009-06-30
DK1419773T3 (da) 2008-09-22
EP1419773B1 (en) 2008-06-04

Similar Documents

Publication Publication Date Title
BR0016635A (pt) Moduladores de neurotransmissão de dopamina
BR0016611A (pt) Moduladores de neurotransmissão de dopamina
BR0003365A (pt) Composições farmacêuticas
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
BR0209468A (pt) Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
CL2004000174A1 (es) Compuestos derivados de malonamida n,n'-disustituidos; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de la enfermedad de alzheimer.
DK1648432T3 (da) Anvendelse af rotigotin til behandling af depressioner
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
BR0213452A (pt) Derivados de piperazina com atividade antagonista receptora de ccr1
BRPI0411017A (pt) indóis 3-substituìdos e derivados dos mesmos como agentes terapêuticos
BRPI0513672A (pt) processo aperfeiçoado para a preparação de 2h-1-benzopiran-2metanol, (alfa). (alfa)' [iminobis (metileno)] bis [6-fluoro-3, 4-dihidro, [2r* [r* [r* (s*)]]]], composição farmacêutica, forma t1 amorfa, e processo para a preparação da forma t1 de hidrocloreto de nebivolol
BRPI0414011A (pt) naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos
BR9812088A (pt) Combinação de componentes, uso desta, processos para a preparação da mesma, para o tratamento de distúrbios afetivos, para o tratamento de depressão, e para melhorar o inìcio de ação terapêutica, formulação farmacêutica, e, kit
BRPI0415769A (pt) alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as
BRPI0411092A (pt) benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos
BR9812236A (pt) Combinação de componentes, uso desta, processos para a preparação da mesma, para o tratamento de distúrbios afetivos, para o tratamento de depressão, e para melhorar o inìcio de ação terapêutica, formulação farmacêutica, e, kit
BRPI0408205A (pt) derivado de anilina substituìdo, composição farmacêutica, e, uso de uma composição farmacêutica
BR0214649A (pt) Derivados de aminotetralina como antagonistas do receptor muscarìnico
DE60002583D1 (de) Benzofurylpiperazine als serotonin-agonisten
BRPI0415625A (pt) uso de um derivado de halogeneto de ácido hidroxìmico no tratamento de hidroxìmico no tratamento de doenças neurogenerativas
ATE152716T1 (de) Benzopyrane und diese enthaltende pharmazeutische zusammenstellungen
BR0106248A (pt) Inibidores de metaloprotease, processo para a sua preparação e composições farmacêuticas contendo os mesmos
BR0312852A (pt) Emprego de cilobradina ou os sais farmaceuticamente aceitáveis desta para o tratamento ou prevenção de insuficiência cardìaca
ATE201684T1 (de) Neue 4-(3-benzofuranyl) piperidinyl und 4-(3- benzothienyl) piperidinyl-derivate und diese enthaltende pharmazeutische zusammenstellungen

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: A. CARLSSON RESEARCH AB (SE)

Free format text: A FIM DE ATENDER A PETICAO DE TRANSFERENCIA NO 020090041230/RJ DE 30/04/2009, ESCLARECA A DIVERGENCIA ENTRE OS NOMES DO TITULAR DO PEDIDO DE PATENTE E O NOME DO CEDENTE DA REFERIDA PETICAO.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: A. CARLSSON RESEARCH AB (SE)

Free format text: REFERENTE A RPI 2015 DE 18/08/2009, CODIGO DO DESPACHO (25.3), POR TER SIDO INDEVIDO.

B25D Requested change of name of applicant approved

Owner name: NEUROSEARCH SWEDEN AB (SE)

Free format text: ALTERADO DE: A. CARLSSON RESEARCH AB

B25G Requested change of headquarter approved

Owner name: NEUROSEARCH SWEDEN AB (SE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080114423/RJ DE 28/08/2008.

B25A Requested transfer of rights approved

Owner name: NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK

Free format text: TRANSFERIDO DE: NEUROSEARCH SWEDEN AB

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]